Sector: Health Care
Director information for ELI LILLY (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carolyn Bertozzi | Independent Director | 59 | ["Professor of Chemistry, Stanford University", "Investigator, Howard Hughes Medical Institute"] | ["Ethics and Compliance", "Science and Technology"] | 2026 |
| Carolyn R. Bertozzi, Ph.D. | 59 | ["Nobel Laureate", "expert in chemical biology", "decades of groundbreaking research experience", "founding and advising various biotechnology companies", "commercialization experience in life sciences"] | ["Ethics and Compliance", "Science and Technology"] | 2026 | |
| Dave Ricks | Chair, President, and Chief Executive Officer | ["Leadership in generating positive clinical data", "Oversaw significant company revenue and earnings growth", "Experience with FDA and European Commission approvals", "Management of major manufacturing investments", "Acquisitions of several biotechnology companies", "Expansion of direct-to-patient platforms", "Initiatives with AI and government partnerships"] | [] | 2026 | |
| David A. Ricks | Chair, President, and CEO; President, CEO and Chair | 58 | ["Over 25 years of experience at Lilly", "Led and shaped large-scale operations globally", "Oversaw substantial revenue growth and shareholder return", "Experience in marketing, sales, drug development, and international operations", "Significant experience in public policy", "Chair", "President and Chief Executive Officer, Eli Lilly and Company"] | [] | 2026 |
| Gabrielle Sulzberger | Director | 65 | ["Over 30 years of experience advising public and privately held companies in consumer products, retail, financial services, and life sciences", "Chair of global ESG advisory at Teneo", "Corporate governance experience through work with corporate boards, both as a board member and as a governance committee chair", "Experience in private equity and helping companies navigate disruption and transformation", "Chief financial officer of several publicly and privately held companies", "Audit committee chair of several public companies", "Audit Committee Financial Expert"] | ["Audit", "Directors and Corporate Governance"] | 2026 |
| Jamere Jackson | Chief Financial Officer; Chair | 57 | ["significant global financial experience", "strong background in strategic planning", "knowledge of international business operations", "management of complex financial risks", "experience in finance and accounting", "roles in strategic planning and mergers and acquisitions"] | ["Audit", "Directors and Corporate Governance"] | 2026 |
| J. Erik Fyrwald | Chief Executive Officer | 66 | ["Deep understanding of operational and strategic leadership", "International business experience", "Experience in leading international companies", "Focus on technology and digital innovation", "Significant corporate governance experience", "Membership in various board of directors of international companies"] | ["Talent and Compensation", "Science and Technology"] | 2026 |
| Jon Moeller | Independent Director; Executive Chairman | 61 | ["Executive Chairman", "Former Chairman", "President and Chief Executive Officer, The Procter & Gamble Company", "Extensive leadership experience", "Financial acumen", "Strategic vision", "Commitment to high standards of corporate governance", "Experience in navigating complex regulatory environments", "Ability to drive growth and innovation", "Experience in managing supply chain and operational strategies"] | ["Audit", "Directors and Corporate Governance"] | 2026 |
| Juan R. Luciano | Lead Independent Director; Chair | 64 | ["Chair and chief executive officer of a major global enterprise", "Leader of large organizations", "Expertise in international business, strategy, and operations", "Experience in highly regulated sectors", "Strong leader and direct feedback provider"] | ["Talent and Compensation", "Directors and Corporate Governance"] | 2026 |
| Katherine Baicker, Ph.D. | Director | 54 | ["Experience in health economics research and policy", "Former economic advisor to the White House", "Health advisor to the Congressional Budget Office", "Leadership of a research and educational institution", "Involvement with medical and health system research organizations", "Experience with government perspectives in healthcare"] | ["Ethics and Compliance (Chair)", "Science and Technology"] | 2026 |
| Kimberly Johnson | Vice President and Chief Operating Officer | 53 | ["Considerable financial and operational experience", "Strong background in technology, governance, talent management, and strategy for global risk management", "Leadership over various departments focused on cybersecurity, technology, operations, account services, enterprise change, data, modeling, analytics, information security, resiliency, innovation, and corporate strategy", "Deep understanding of enterprise risk management as chief risk officer of Fannie Mae", "Oversaw enterprise risk at T. Rowe Price", "Led Fannie Mae\u2019s digital transformation and established a four-year enterprise modernization plan"] | ["Talent and Compensation", "Ethics and Compliance"] | 2026 |
| Mary Lynne Hedley, Ph.D. | Director | 63 | ["Extensive business leadership and scientific investigation experience in the biotechnology industry", "Experience leading and overseeing complex operations and risks of biotechnology companies", "Expertise in FDA regulatory pathways and achieving drug approvals", "Experience with developing and commercializing pharmaceutical products", "Service on boards of directors and board committees of other public companies and not-for-profits"] | ["Ethics and Compliance", "Science and Technology"] | 2026 |
| Ralph Alvarez | Director | 70 | ["more than 40 years of experience in consumer marketing", "global operations", "international business", "strategic planning", "extensive executive leadership experience", "in-depth knowledge of consumer marketing, talent and brand management", "understanding of international markets and operations", "strong perspective on how to motivate, develop, and engage diverse talent", "Audit Committee Financial Expert"] | ["Audit", "Talent and Compensation"] | 2026 |
| William G. Kaelin, Jr., M.D. | Director | 68 | ["Nobel Laureate", "scientist", "academician", "physician", "decades of preeminent medical research and discovery experience", "professor and mentor", "investigator at Howard Hughes Medical Institute", "commercialization experience through venture capital funds and biotechnology companies"] | ["Directors and Corporate Governance", "Science and Technology"] | 2026 |
| William Kaelin, Jr. | Independent Director | 68 | ["Sidney Farber Professor of Medicine, Harvard Medical School", "Professor, Dana-Farber Cancer Institute", "Investigator, Howard Hughes Medical Institute"] | ["Directors and Corporate Governance", "Science and Technology (Chair)"] | 2026 |
